Citigroup
RGC icon

Citigroup’s Regencell Bioscience RGC Stock Holding History

Citigroup’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2K Buy
1,831
+1,830
+183,000% +$44K ﹤0.01% 5230
2026
Q1 		$25 Buy
+1
New +$28 ﹤0.01% 5686
2025
Q3 		– Sell
-70
Closed -$1.19K – 6281
2025
Q2 		$1.19K Buy
+70
New +$854 ﹤0.01% 5397
2022
Q2 		– Sell
-85,120
Closed -$48K – 6583
2022
Q1 		$48K Buy
+85,120
New +$73K ﹤0.01% 4744

Other funds holding RGC

FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $45.6B AUM 44.74% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

Citigroup's RGC Position: Q2 2026 in Review

Citigroup increased its Regencell Bioscience (RGC) stake by 183,000% in Q2 2026, buying an estimated $44K and bringing the position to 1,831 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5230.

Citigroup first reported a position in RGC in Q1 2022 and has held it in 4 quarters since. The position peaked at $48K in Q1 2022. 8 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Citigroup held 1,831 shares of Regencell Bioscience worth $11.2K as of Q2 2026.
  • Citigroup bought 1,830 Regencell Bioscience shares in Q2 2026, an estimated $44K.
  • Regencell Bioscience made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5230 holding.
  • Citigroup first reported a position in Regencell Bioscience in Q1 2022 and has held it in 4 quarters since.
  • Citigroup's Regencell Bioscience position peaked at $48K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.